Atherogenic dyslipidemia and risk of silent coronary artery disease in asymptomatic patients with type 2 diabetes: a cross-sectional study. - Wikidata - wikimedia - TriplyDB

Atherogenic dyslipidemia and risk of silent coronary artery disease in asymptomatic patients with type 2 diabetes: a cross-sectional study.

Atherogenic dyslipidemia and risk of silent coronary artery disease in asymptomatic patients with type 2 diabetes: a cross-sectional study.

http://www.wikidata.org/entity/Q37119482

about

Association of statin use and hypertriglyceridemia with diabetic macular edema in patients with type 2 diabetes and diabetic retinopathy Correlation between Glycated Hemoglobin and Triglyceride Level in Type 2 Diabetes Mellitus.Evolution of silent myocardial ischaemia prevalence and cardiovascular disease risk factor management in Type 2 diabetes over a 10-year period: an observational study.Apolipoprotein A-I exchange is impaired in metabolic syndrome patients asymptomatic for diabetes and cardiovascular disease.Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia.Relation between low-density lipoprotein cholesterol/apolipoprotein B ratio and triglyceride-rich lipoproteins in patients with coronary artery disease and type 2 diabetes mellitus: a cross-sectional study.Omega-3 polyunsaturated fatty acids supplementation in patients with diabetes and cardiovascular disease risk: does dose really matter?Cardiovascular risk profile of patients with atherogenic dyslipidemia in middle age Lithuanian population

P2860

Q37569809-160B7FA2-DA59-4338-9527-BFC417167F18 Q38676426-08383DFD-26D2-4FCD-B8CA-FB4C76E20972 Q40238177-7F37296F-46E3-40C5-8A0D-EB13CDC4A225 Q41216100-D1487E1C-7BC6-4ED2-A5F0-82E1DA2BBB85 Q42278957-BCA85112-8C89-4489-826A-DA1A584825CC Q42284569-4BFF8BEA-106B-4151-963B-5BB4594EBCAE Q58699954-37874C76-EAED-4B68-B4C4-E4B1611D7164 Q58763793-D207766C-7861-4D87-9B05-8603F458319F

P2860

Atherogenic dyslipidemia and risk of silent coronary artery disease in asymptomatic patients with type 2 diabetes: a cross-sectional study.

http://www.wikidata.org/entity/Q37119482

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 22 July 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Atherogenic dyslipidemia and r ...... etes: a cross-sectional study.

@en

Atherogenic dyslipidemia and r ...... etes: a cross-sectional study.

@nl

type

label

Atherogenic dyslipidemia and r ...... etes: a cross-sectional study.

@en

Atherogenic dyslipidemia and r ...... etes: a cross-sectional study.

@nl

prefLabel

Atherogenic dyslipidemia and r ...... etes: a cross-sectional study.

@en

Atherogenic dyslipidemia and r ...... etes: a cross-sectional study.

@nl

P1433

Q37119482-BF0312E8-3A7B-4C64-B544-16B4BEE59A6F

P1476

Q37119482-F31A8FA0-793F-492A-A9A2-E529B0DD062E

P2093

Q37119482-621F1FD9-458D-4A45-90BC-34BE34C0C045

Q37119482-9E559FFA-30A5-4B44-84B6-6A27C192C924

Q37119482-C84CF1DE-3DEF-4477-8F97-A23B04C537DF

Q37119482-D94C96C1-1564-46F2-A33E-B60AB37658D6

Q37119482-F201FCCB-13E8-43CB-8CEA-E74A25FF0D6B

P2860

Q37119482-00440543-2023-464C-907F-8B5D693D7534

Q37119482-03525E81-B441-465A-BB98-2D2E2B918565

Q37119482-0F4C2A74-0667-4CE1-9889-90B468704171

Q37119482-0FA88857-13C3-4CED-B283-D8C9E6D3E428

Q37119482-215AA25E-20D7-4571-A725-7406957DAA7C

Q37119482-26284819-CD62-4825-9908-0C8FB2A59683

Q37119482-28654B4F-D9C8-4999-9E37-0B127825A2A9

Q37119482-2F64EC7E-1FE1-4775-83A7-5F5C95A1983B

Q37119482-3116ADFC-0828-49DF-9611-144BE19E7B87

Q37119482-37F588B7-C7AB-4966-8823-70C829E512B0

P2888

Q37119482-BD74AE64-9ADC-4A13-8AC6-7A39B0DC7032

P304

Q37119482-3C32ADFB-F21C-4BDE-A78A-5AA6DC1212A8

P31

Q37119482-E266FC44-A73F-447A-93EB-3FC933EEEBAC

P356

Q37119482-AB8F3E2F-9A0C-4DA7-BEB6-72767F9C4125

P407

Q37119482-0BE837FB-6111-496D-BBEA-3B92B81DE319

P433

Q37119482-69AD5DC6-FA70-4854-8B15-16490794FFD2

P478

Q37119482-03F74A25-D38D-4A93-B57B-8087AB899ADA

P50

Q37119482-5E33DEF7-0F15-4B27-A4C0-BE589EDEBEB6

P577

Q37119482-AF36723C-EA5A-41ED-94C1-E37866CB89C1

P6179

Q37119482-47AC491C-8B92-44CF-A24D-F22C66666C95

P698

Q37119482-71DADA67-B7A9-48F8-92ED-802A568EFA0B

P921

Q37119482-0250AAEF-1F8A-4F9D-9638-75E6C03F21C7

Q37119482-44B08305-165A-46D2-9E36-19A5903DFB8A

Q37119482-F6651A10-1BE9-4203-9518-3B126B4413E9

P932

Q37119482-E98CEB0E-67A3-4E6F-931D-3D205C7E989D

P356

S12933-016-0415-4

P1433

Cardiovascular Diabetology

P1476

Atherogenic dyslipidemia and r ...... betes: a cross-sectional study

@en

P2093

Antoine Avignon

http://www.w3.org/2001/XMLSchema#string

Ariane Sultan

http://www.w3.org/2001/XMLSchema#string

Bernard Chanu

http://www.w3.org/2001/XMLSchema#string

Minh Tuan Nguyen

http://www.w3.org/2001/XMLSchema#string

Paul Valensi

http://www.w3.org/2001/XMLSchema#string

P2860

Prevalence, incidence, predictive factors and prognosis of silent myocardial infarction: A review of the literature

Residual macrovascular risk in 2013: what have we learned?

Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial

Lipids, lipid-lowering therapy and diabetes complications.

Effects of combination lipid therapy in type 2 diabetes mellitus.

Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

P2888

s12933-016-0415-4

P304

104

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12933-016-0415-4

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Emmanuel Cosson

P577

2016-07-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1025112103

http://www.w3.org/2001/XMLSchema#string

P698

27450534

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

type-2 diabetes

P932

4957891

http://www.w3.org/2001/XMLSchema#string